花旗：美国医疗科技_2025 年展望_但等等，还有更多

09 Jul 2025 05:00:00 ET │ 78 pages US MedTech 2Q25 Preview: But Wait, There's More CITI'S TAKE At the mid-year 2025 mark it has already been a long year, given macro- economic headlines (including tariffs) and uncertainty the new normal. MedTech has largely withstood the healthcare headwinds but has been caught in the macro. While tariffs seem to have been normalized or at least absorbed, with the 90-day pause on April 2 reciprocal tariffs extended to August 1, and the U.S.-China pause expiring August 12 up ...